Adicet Q2 net loss $32.4M; ADI-001 shows 71% ORR, 63% CR in Phase 1 NHL

Adicet Bio, Inc.

2023-Q2 EPS reported -$1.47

Q2 net loss $32.4M ($0.75/share) vs $22.5M ($0.56) in Q2 2022; R&D expenses rose to $28.4M.
ADI-001 Phase 1 data: 71% ORR, 63% CR across all dose levels in heavily pretreated NHL (median 4 prior lines); no DLTs/GvHD.
Plan to initiate pivotal Phase 2 study in post-CAR T LBCL under accelerated approval in 2024; expansion cohort EXPAND starting.
IND for ADI-925 (solid tumors) expected H2 2023; IND for ADI-270 (renal cell carcinoma) expected H1 2024.
Cash $205.5M as of June 30, 2023; runway into H1 2025. Appointed Katie Peng to Board in July.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Adicet Bio, Inc. reported the quarter ended June 30, 2023 results: net income $32.4 million, EPS $0.75 per basic and diluted share.

Period: the quarter ended June 30, 2023
Net income: $32.4 million
EPS: $0.75 per basic and diluted share
Result: reported results

Exact text from the filing

Net loss for the three months ended June 30, 2023 was $32.4 million, or a net loss of $0.75 per basic and diluted share

View on SEC.gov

Browse all earnings releases →

Adicet Bio, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-23-040617

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.